| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
33,249 |
31,224 |
$2.30M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,897 |
14,311 |
$1.48M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
8,804 |
8,804 |
$809K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
19,190 |
19,109 |
$765K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
8,811 |
8,579 |
$763K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,295 |
4,295 |
$394K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
4,969 |
4,914 |
$194K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
18,132 |
18,126 |
$154K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
10,448 |
10,245 |
$151K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
5,196 |
5,126 |
$146K |
| 99215 |
Prolong outpt/office vis |
613 |
602 |
$86K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
395 |
395 |
$39K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
220 |
213 |
$19K |
| 96161 |
|
3,295 |
3,110 |
$16K |
| 87807 |
|
1,365 |
1,352 |
$16K |
| 99381 |
|
156 |
156 |
$15K |
| 99188 |
|
1,268 |
1,268 |
$14K |
| 83655 |
|
849 |
849 |
$9K |
| 96127 |
|
1,297 |
1,295 |
$9K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
241 |
239 |
$9K |
| 85018 |
|
1,871 |
1,870 |
$4K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
103 |
102 |
$4K |
| 99460 |
|
28 |
28 |
$2K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
29 |
29 |
$2K |
| 0072A |
|
33 |
33 |
$1K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
14 |
14 |
$1K |
| 54150 |
|
12 |
12 |
$1K |
| 99173 |
|
263 |
263 |
$640.73 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
40 |
40 |
$637.15 |
| 0071A |
|
15 |
15 |
$600.00 |
| 96380 |
|
18 |
18 |
$354.06 |
| 99051 |
|
30 |
30 |
$202.50 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
39 |
39 |
$72.06 |
| 96160 |
|
4,731 |
4,731 |
$24.86 |
| 90686 |
|
1,905 |
1,904 |
$20.15 |
| 36416 |
|
12 |
12 |
$13.35 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
14 |
14 |
$0.56 |
| 90670 |
|
3,695 |
3,693 |
$0.00 |
| 90707 |
|
139 |
139 |
$0.00 |
| 90633 |
|
995 |
995 |
$0.00 |
| 90681 |
|
1,219 |
1,218 |
$0.00 |
| 90700 |
|
105 |
105 |
$0.00 |
| 90661 |
|
197 |
197 |
$0.00 |
| 90710 |
|
24 |
24 |
$0.00 |
| 90672 |
|
99 |
99 |
$0.00 |
| 90677 |
|
593 |
593 |
$0.00 |
| 90647 |
|
2,811 |
2,810 |
$0.00 |
| 90723 |
|
2,958 |
2,955 |
$0.00 |
| 90716 |
|
160 |
160 |
$0.00 |
| 90674 |
|
382 |
382 |
$0.00 |
| 90381 |
|
13 |
13 |
$0.00 |
| 90651 |
|
12 |
12 |
$0.00 |